Cancer in the HIV-Infected Host: Epidemiology and Pathogenesis in the Antiretroviral Era

Brickman, Cristina; Palefsky, Joel M.

doi:10.1007/s11904-015-0283-7

Cited by 39 publications

(36 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HIVIIs are a unique group of patients in the context of HNSCC. They have greater exposure to tobacco and alcohol, have impaired immune function, and consequently are more prone to infection by high‐risk HPV . In this way, these patients have multiple key risk factors for the development of cancer and particularly HNSCC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Distinct pattern of TP53 mutations in human immunodeficiency virus–related head and neck squamous cell carcinoma

Gleber‐Netto

Zhao

Trivedi

et al. 2017

Cancer

View full text Add to dashboard Cite

BACKGROUND Human immunodeficiency virus–infected individuals (HIVIIs) have a higher incidence of head and neck squamous cell carcinoma (HNSCC), and clinical and histopathological differences have been observed in their tumors in comparison with those of HNSCC patients without a human immunodeficiency virus (HIV) infection. The reasons for these differences are not clear, and molecular differences between HIV‐related HNSCC and non–HIV‐related HNSCC may exist. This study compared the mutational patterns of HIV‐related HNSCC and non–HIV‐related HNSCC. METHODS The DNA of 20 samples of HIV‐related HNSCCs and 32 samples of non–HIV‐related HNSCCs was sequenced. DNA libraries covering exons of 18 genes frequently mutated in HNSCC (AJUBA, CASP8, CCND1, CDKN2A, EGFR, FAT1, FBXW7, HLA‐A, HRAS, KEAP1, NFE2L2, NOTCH1, NOTCH2, NSD1, PIK3CA, TGFBR2, TP53, and TP63) were prepared and sequenced on an Ion Personal Genome Machine sequencer. DNA sequencing data were analyzed with Ion Reporter software. The human papillomavirus (HPV) status of the tumor samples was assessed with in situ hybridization, the MassARRAY HPV multiplex polymerase chain reaction assay, and p16 immunostaining. Mutation calls were compared among the studied groups. RESULTS HIV‐related HNSCC revealed a distinct pattern of mutations in comparison with non–HIV‐related HNSCC. TP53 mutation frequencies were significantly lower in HIV‐related HNSCC. Mutations in HIV+ patients tended to be TpC>T nucleotide changes for all mutated genes but especially for TP53. CONCLUSIONS HNSCC in HIVIIs presents a distinct pattern of genetic mutations, particularly in the TP53 gene. HIV‐related HNSCC may have a distinct biology, and an effect of the HIV virus on the pathogenesis of these tumors should not be ruled out. Cancer 2018;124:84‐94. © 2017 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Kaposi sarcoma and non‐Hodgkin lymphoma are the most common neoplasms among HIVIIs and are AIDS‐defining malignancies. However, since the advent of antiretroviral therapy, the incidence of other malignant tumors (non–AIDS‐defining cancer) has increased, and they have become important causes of death for these patients …”

Section: Introductionmentioning

confidence: 99%

Distinct pattern of TP53 mutations in human immunodeficiency virus–related head and neck squamous cell carcinoma

Gleber‐Netto

Zhao

Trivedi

et al. 2017

Cancer

View full text Add to dashboard Cite

show abstract

“…This estimate was higher than reported earlier in a meta-analysis of 1 in 377 per year among HIV-infected men with HSIL (5). One of the limitations of this study is that the baseline disease classification was based on cytology, which has been shown to have relatively low sensitivity for anal HSIL and underestimate the severity of anal disease (6). Progression from anal HSIL to cancer was also reported to be high in another study.…”

Section: Introductionmentioning

confidence: 99%

“…Most studies of the prevalence or incidence of anal HSIL in the post-ART era continue to show a high prevalence of this cancer precursor lesion in HIV-infected men and women (6). These cross-sectional studies suggest that ART has a limited effect on reducing HSIL incidence or inducing HSIL regression.…”

Section: Introductionmentioning

confidence: 99%

Human papillomavirus-associated anal and cervical cancers in HIV-infected individuals

Palefsky

2017

Current Opinion in HIV and AIDS

Self Cite

View full text Add to dashboard Cite

Purpose of review The incidence of human papillomavirus (HPV)-related cancers has increased (anal cancer) or not declined (cervical cancer) since the introduction of antiretroviral therapy (ART). This article reviews recent data on incidence and prevention efforts for HPV-related cancers in the ART era. Recent findings ART may confer some benefit with respect to reducing the risk of anal HSIL and cancer, but the degree of that benefit appears to be limited. The prevalence of anal HPV infection, anal HSIL and anal cancer remain high among individuals on effective ART. The incidence of cervical cancer is high among HIV-infected women, particularly in countries where there are no organized cervical cancer prevention programs. Efforts are in progress to define optimal screen-and-treat cervical cancer prevention programs in different clinical settings and to define the efficacy of secondary prevention programs for prevention of anal cancer. Summary HPV-related cancers are likely to remain an important problem in HIV-infected men and women for the foreseeable future, even among those on effective ART.

show abstract

“…The availability of highly active antiretroviral therapy (HAART) has not only reduced morbidity and mortality among people living with HIV (PLWH) but has changed the epidemiology of HIV infection [1,2]. Since the advent of HAART in 1996, the population of PLWH has expanded, with particular growth in the group of patients $40 years old [3].…”

Section: Introductionmentioning

confidence: 99%

Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I

et al. 2016

View full text Add to dashboard Cite

Background: Since the advent of combined antiretroviral therapy (ART), the incidence of non-AIDS-defining cancers (non-ADCs) among HIV-positive patients is rising. We previously described HIV testing rates of B5% in our oncology centre, against a local HIV prevalence of 0.4% [1]. We have since worked with the Service of Oncology to identify, how HIV testing can be optimized, we have conducted a study on investigating barriers in HIV-testing oncology patients (IBITOP) among treating oncologists and their patients. Methods: After an initial two-month pilot study to examine feasibility [2], we conducted the first phase of the IBITOP study between 1st July and 31st October 2013. Patients of unknown HIV status, newly diagnosed with solid-organ non-AIDS-defining cancer, and treated at Lausanne University Hospital were invited to participate. Patients were offered HIV testing as a part of their initial oncology work-up. Oncologist testing proposals and patient acceptance were the primary endpoints. Results: Of 235 patients with a new oncology diagnosis, 10 were excluded (7 with ADCs and 3 of known HIV-positive status). Mean age was 62 years; 48% were men and 71% were Swiss. Of 225 patients, 75 (33%) were offered HIV testing. Of these, 56 (75%) accepted, of whom 52 (93%) were tested. A further ten patients were tested (without documentation of being offered a test), which gave a total testing rate of 28% (62/225). Among the 19 patients who declined testing, reasons cited included selfperceived absence of HIV risk, previous testing and palliative care. Of the 140 patients not offered HIV testing and not tested, reasons were documented for 35 (25%), the most common being previous testing and follow-up elsewhere. None of the 62 patients HIV tested had a reactive test. Conclusions: In this study, one third of patients seen were offered testing and the HIV testing rate was fivefold higher than that of previously observed in this service. Most patients accepted testing when offered. As HIV-positive status impacts on the medical management of cancer patients, we recommend that HIV screening should be performed in settings, where HIV prevalence is 0.1%. Phase II of the IBITOP study is now underway to explore barriers to HIV screening among oncologists and patients following the updated national HIV testing guidelines which recommend testing in non-ADC patients undergoing chemotherapy.

show abstract

Cancer in the HIV-Infected Host: Epidemiology and Pathogenesis in the Antiretroviral Era

Cited by 39 publications

References 78 publications

Distinct pattern of TP53 mutations in human immunodeficiency virus–related head and neck squamous cell carcinoma

Distinct pattern of TP53 mutations in human immunodeficiency virus–related head and neck squamous cell carcinoma

Human papillomavirus-associated anal and cervical cancers in HIV-infected individuals

Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I

Contact Info

Product

Resources

About